Per Malmström
91 – 100 of 157
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2006
-
Mark
Topoisomerase II{alpha} Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu-Amplified Breast Cancer: Scandinavian Breast Group Trial 9401.
(
- Contribution to journal › Article
-
Mark
Basoluminal carcinoma: A new biologically and prognostically distinct entity between basal and luminal breast cancer
(
- Contribution to journal › Article
-
Mark
TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer
(
- Contribution to journal › Article
-
Mark
Time dependent effects of tamoxifen treatment on cardiovascular morbidity
(
- Contribution to journal › Published meeting abstract
- 2005
-
Mark
Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.
(
- Contribution to journal › Published meeting abstract
-
Mark
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial
(
- Contribution to journal › Article
-
Mark
Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: Results from a randomized trial
(
- Contribution to journal › Article
-
Mark
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
(
- Contribution to journal › Article
-
Mark
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
(
- Contribution to journal › Article
-
Mark
Estrogen receptor (ER)-beta has favorable independent prognostic value for ER-alfa negative breast cancer patients receiving adjuvant tamoxifen
(
- Contribution to journal › Published meeting abstract